amyotrophic lateral sclerosis

Sep 19, 2017

Thrombolytic Sciences announced completion of Phase I TS01 trial A clinical stage vascular health and biotech company, Thrombolytic Science, LLC (TSI), announced the completion of its Phase I trial investigating TS01, which is a new-generation clot-dissolving therapy for the treatment of clot-induced diseases like i...

Aug 26, 2016

The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional  $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...

Dec 20, 2014

Gene Therapy: The “Hunt” for CNS disorders! Many companies have tried over the years to find a way to reverse the course of crippling central nervous system disorders like amyotrophic lateral sclerosis (a.k.a. Lou Gehrig’s disease) but have failed. Fortunately, Gene therapy has proven to be an answer to a wide ran...